Histological regression of gastrointestinal peritoneal metastases after systemic chemotherapy
Peritoneal metastases (PM) are relatively resistant to systemic chemotherapy, and data on histological response to therapy is rare. The aim of this study was to quantify the treatment response of PM after systemic chemotherapy.
Main Authors: | Toussaint Laura, Teixeira Farinha Hugo, Barras Jean-Luc, Demartines Nicolas, Sempoux Christine, Hübner Martin |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2021-07-01
|
Series: | Pleura and Peritoneum |
Subjects: | |
Online Access: | https://doi.org/10.1515/pp-2021-0118 |
Similar Items
-
Is pressurized intraperitoneal aerosol chemotherapy safe and effective in the treatment of peritoneal metastases from pancreatic adenocarcinoma?
by: Krzysztof Smoluchowski, et al.
Published: (2020-09-01) -
Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review
by: Magnus Ploug, et al.
Published: (2020-02-01) -
Radiologist Checklist for Selecting Patients to Undergo PIPAC (Pressurized IntraPeritoneal Aerosol Chemotherapy)
by: Elena Rodolfino, et al.
Published: (2021-09-01) -
A Phase I Dose Escalation Study of Oxaliplatin, Cisplatin and Doxorubicin Applied as PIPAC in Patients with Peritoneal Carcinomatosis
by: Manuela Robella, et al.
Published: (2021-03-01) -
Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma
by: Urs Giger-Pabst, et al.
Published: (2018-04-01)